|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.02.26 - 22:09
|
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference (GlobeNewswire EN)
|
|
|
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in a fireside chat as part of the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 at 9:50 a.m. ET....
|
|
|
23.02.26 - 22:09
|
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 (Business Wire)
|
|
|
HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026
HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed
Phase III ILLUMINE Study in 1L PD-L1 Positive R/M HNSCC Sponsored by Cooperative Group, GORTEC, to Initiate; First Patient Expected in Early Q2 2026
US FDA Accepts BLA Filing Based on HARMONi Study; PDUFA Goal Action Date of November 14, 2026
First Patient Dosed in Revolution Medicines Clinical Trial Collaboration Evaluating Ivonescimab in Combination with RAS(ON) Inhibitors in RAS Mutant Tumors
GSK Collaboration Clinical Trials Evaluating Ivonescimab in Combination with GSK's Novel B7-H3, Risvutatug Rezetecan, Expected to Start Mid-2026MIAMI--(BUSINESS WIRE)--$SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the fourt...
|
|
|
18.02.26 - 22:09
|
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 (GlobeNewswire EN)
|
|
|
REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, February 25, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress....
|
|
|
|
|
|
|
|
|
27.01.26 - 11:06
|
Tubulis Adds Steve Kelsey as Independent Director to its Advisory Board (Business Wire)
|
|
|
Appointment brings additional precision oncology expertise as company accelerates development of its ADC pipeline
MUNICH--(BUSINESS WIRE)--Tubulis today announced the appointment of Steve Kelsey, MD, as independent director to its Advisory Board. Dr. Kelsey, currently President, Research and Development at Revolution Medicines, brings more than two decades of global biotechnology experience spanning small molecules, antibodies and antibody drug conjugates (ADCs), with a strong track record of translating innovative science into approved and transformative oncology therapies. As independent director, he will provide strategic guidance as the company advances its ADC lead candidates, TUB-030 and TUB-040, through later-stage clinical development and continues to expand its pipeline.
“Steve is an outstanding drug developer with a mindset that perfectly aligns with our objective to change clinical paradigms and improve patient outcomes,” said Dr. Dominik Schumacher, Chief Executive Officer and Co-founder o...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
